FSSAI orders statutory audit of 27 Dabur product lines over labelling and health claims

FSSAI has reportedly expanded scrutiny of Dabur India, seeking a statutory audit across 27 product lines, including honey, oils and vinegar, over medicinal and health claims. The regulator has also sought label corrections, while a Delhi High Court stay remains in place on its earlier action against select “100%” claims.

— Source publishedThu, 17 Sept, 2026, 15:03 IST·First seen Thu, 17 Sept, 2026, 15:06 IST·Source Mint

What happened

Dabur India · FSSAI has sought a statutory audit of 27 Dabur product lines over medicinal and health claims, including oils, vinegar and honey. The regulator

Key facts

  • 27 product lines
  • six companies
  • 100% Pure
  • 100% Natural
  • 100% Purity Guaranteed
  • 100% Organic
  • 100% Tender Coconut Water
  • FSS (Advertising & Claims) Regulations, 2018
  • August 19
  • August 24

Why this matters

Any partnership or acquisition involving Dabur’s health-positioned FMCG portfolio should include rigorous diligence on claim substantiation, labelling controls and regulatory exposure.

What to watch

  • FSSAI audit scope, deadlines, named SKUs and whether it expands beyond honey, oils and vinegar.
  • Any show-cause notice, recall, sales restriction, penalty or mandatory corrective-advertising order.
  • Delhi High Court rulings on the existing stay and their applicability to other Dabur claims.
  • Dabur disclosures on provisions, inventory write-offs, legal expenses, advertising changes or audit outcomes.
  • Evidence of competitor scrutiny, which would indicate an industry-wide tightening of FMCG health-claim enforcement.
  • Changes in e-commerce listings, packaging imagery or consumer complaints for affected products.
  • Commission an independent claim-substantiation and label audit across all wellness, immunity, medicinal and purity claims, not only the 27 named lines.
  • Freeze new packaging and advertising that uses absolute, therapeutic, disease-adjacent or '100%' language until legal and scientific review is complete.
  • Build a phased relabelling plan by inventory age, channel exposure and product revenue contribution to minimize write-offs.
  • Strengthen evidence files for each claim, including ingredient specifications, laboratory testing, consumer-facing qualifiers and applicable FSSAI permissions.
  • Prepare retailer, distributor and customer-service guidance to prevent inconsistent in-market messaging during label transitions.
  • Model downside from packaging obsolescence, promotional withdrawal, possible fines and reduced conversion in health-positioned categories.

Also reported by